Skip to content

Study · Systematic review · n = 172 · 2016

6 results

A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.

Niafar M, Pourafkari L, Porhomayon J, Nader N

Archives of gynecology and obstetrics10 Dec 2015Cited by 43 (Europe PMC)

PMID26660657 (opens in a new tab)DOI10.1007/s00404-015-3976-7 (opens in a new tab)PepBankPUB-26660657
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In women with PCOS, body mass index fell significantly after 3 months of liraglutide treatment.

    In plain wordsIn women with PCOS, body mass index went down after 3 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index change
    Study

    n = 172

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    BMI change
    −1.65 Kg/m(2)
    after 3 months

    Source sentences

    Summary
    BMI significantly dropped by -1.65 (0.72-2.58) Kg/m(2) after 3 months treatment with liraglutide
    2 context sentences
    Summary · context
    Seven RCTs where women with PCOS were treated with liraglutide were identified.
    Summary · context
    The variables that were examined before and after a 90-day treatment included waist circumference, body mass index (BMI), fasting insulin concentrations, insulin resistance using homeostatic model (HOMA-IR), serum testosterone, and sex hormone-binding globulin (SHBG).
  2. 02HumanSystematic reviewEfficacy outcome

    In women with PCOS, waist circumference did not change significantly after 3 months of liraglutide treatment.

    In plain wordsIn women with PCOS, waist size did not change clearly after 3 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeWaist circumference
    Study

    n = 172

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    waist circumference did not change significantly.
    2 context sentences
    Summary · context
    Seven RCTs where women with PCOS were treated with liraglutide were identified.
    Summary · context
    The variables that were examined before and after a 90-day treatment included waist circumference, body mass index (BMI), fasting insulin concentrations, insulin resistance using homeostatic model (HOMA-IR), serum testosterone, and sex hormone-binding globulin (SHBG).
  3. 03HumanSystematic reviewEfficacy outcome

    In women with PCOS, fasting insulin levels did not change significantly after liraglutide treatment.

    In plain wordsIn women with PCOS, fasting insulin levels did not change clearly with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting insulin
    Study

    n = 172

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, fasting insulin levels, insulin sensitivity, and SHBG did not change significantly.
    2 context sentences
    Summary · context
    Seven RCTs where women with PCOS were treated with liraglutide were identified.
    Summary · context
    The variables that were examined before and after a 90-day treatment included waist circumference, body mass index (BMI), fasting insulin concentrations, insulin resistance using homeostatic model (HOMA-IR), serum testosterone, and sex hormone-binding globulin (SHBG).
  4. 04HumanSystematic reviewEfficacy outcome

    In women with PCOS, insulin sensitivity did not change significantly after liraglutide treatment.

    In plain wordsIn women with PCOS, insulin sensitivity did not change clearly with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeInsulin sensitivity
    Study

    n = 172

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, fasting insulin levels, insulin sensitivity, and SHBG did not change significantly.
    2 context sentences
    Summary · context
    Seven RCTs where women with PCOS were treated with liraglutide were identified.
    Summary · context
    The variables that were examined before and after a 90-day treatment included waist circumference, body mass index (BMI), fasting insulin concentrations, insulin resistance using homeostatic model (HOMA-IR), serum testosterone, and sex hormone-binding globulin (SHBG).
  5. 05HumanSystematic reviewEfficacy outcome

    In women with PCOS, sex hormone-binding globulin did not change significantly after liraglutide treatment.

    In plain wordsIn women with PCOS, sex hormone-binding globulin levels did not change clearly with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeSex hormone-binding globulin
    Study

    n = 172

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, fasting insulin levels, insulin sensitivity, and SHBG did not change significantly.
    2 context sentences
    Summary · context
    Seven RCTs where women with PCOS were treated with liraglutide were identified.
    Summary · context
    The variables that were examined before and after a 90-day treatment included waist circumference, body mass index (BMI), fasting insulin concentrations, insulin resistance using homeostatic model (HOMA-IR), serum testosterone, and sex hormone-binding globulin (SHBG).
  6. 06HumanSystematic reviewEfficacy outcome

    In women with PCOS, serum testosterone decreased significantly after liraglutide treatment.

    In plain wordsIn women with PCOS, blood testosterone went down after liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum testosterone change
    Study

    n = 88

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Serum testosterone decrease
    0.29 nmol/L
    88 women

    Source sentences

    Summary
    However, serum testosterone decreased by 0.29 nmol/L in 88 women (P = 0.0003).
    2 context sentences
    Summary · context
    Seven RCTs where women with PCOS were treated with liraglutide were identified.
    Summary · context
    The variables that were examined before and after a 90-day treatment included waist circumference, body mass index (BMI), fasting insulin concentrations, insulin resistance using homeostatic model (HOMA-IR), serum testosterone, and sex hormone-binding globulin (SHBG).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.